Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Health System Reforms Are Opening Gates To Creating Gigantic Pharmacy Chains, Says One Would-be Titan

This article was originally published in PharmAsia News

Executive Summary

BEIJING - The first phase of Beijing's healthcare reforms, centered on expanding medical facilities across the hinterland and extending insurance coverage to rural residents, is creating massive opportunities for drug retailers to form giant chain stores to march through and occupy the Chinese countryside, say the leaders of would-be giant BioPharm Asia

You may also be interested in...



Squeezed by Price Caps And Rising Costs, China's Nepstar Drugstore Chain Pushes Its Own Brands

Want to get beverages on a drug store run for aspirin in China? Not a problem in Nepstar stores, where China's largest retail pharmacy chain is increasingly becoming more of a convenience store than a traditional drug store. It is shifting its business model to focus on private label products to fend off a double squeeze: swelling rental and labor costs and ongoing governmental reform initiatives to impose price caps on drug retailers

Squeezed by Price Caps And Rising Costs, China's Nepstar Drugstore Chain Pushes Its Own Brands

Want to get beverages on a drug store run for aspirin in China? Not a problem in Nepstar stores, where China's largest retail pharmacy chain is increasingly becoming more of a convenience store than a traditional drug store. It is shifting its business model to focus on private label products to fend off a double squeeze: swelling rental and labor costs and ongoing governmental reform initiatives to impose price caps on drug retailers

Liver Cancer Drug Market To Triple By 2014; MNCs Will Take Lead

SHANGHAI - Sales of hepatocellular carcinoma drugs in China will nearly triple from $53 million in 2009 to $144 million in 2014, a new research report from Decision Resources found

Related Content

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel